Natural killer cells

#Genetics #Natural killer cells #Neuroscience #Parkinson's disease #Precision medicine

Precision therapies for Parkinson’s Disease

In this contribution to the Fall 2026 issue of DDW, Dr Andrew French PhD, Dr Richard Boyd PhD, Prof Alice Pébay PhD, and Prof Alan Trounson PhD, explore emerging research into NK cell-derived extracellular vesicles (NK-EVs) as a potential therapeutic platform for neurodegenerative disease. Neurodegenerative diseases… Read More

#Exclusive Content

Non-Hodgkins lymphoma
#CAR-T #Cell therapy #Lymphoma #Natural killer cells #Phase I trial

CAR-NK therapy treats incurable lymphoma in Phase I trial

In a Phase I trial, single-agent CD19 CAR-NK natural killer cell therapy has achieved complete responses in two patients with third-line Waldenstrom macroglobulinemia (WM), a type of non-Hodgkins lymphoma (NHL).  QUILT-106 is a first-in-human trial evaluating the safety and preliminary efficacy of CD19 CAR-NK cell therapy alone… Read More

#Cancer Research #News #Trending News

Natural killer cells
#CAR-T #Natural killer cells #Oncology #Ovarian cancer #UCLA

Scientists develop CAR-NKT cell therapy for ovarian cancer

A new type of immunotherapy called CAR-NKT cell therapy has been shown to be more effective at fighting ovarian cancer than conventional CAR-T cell therapy.   Unlike current cellular immunotherapies that require patient-specific manufacturing and can cost hundreds of thousands of dollars, CAR-NKT cells can be produced… Read More

#Cancer Research #Editor's Choice #News

Oslo stock exchange
#Cell therapy #Celluna #Natural killer cells #Oncology #Solid tumours

First cell therapy company lists on the Oslo Stock Exchange

Zelluna, a developer of allogeneic ‘off the shelf’ T cell receptor based natural killer (TCR-NK) cells for the treatment of cancer, has announced the successful completion of a Business Combination and Private Placement on the Oslo Stock Exchange.  The share capital increases relating to the issuance of… Read More

#Business & Investment #News

Natural killer cells
#Alzheimer's #Cell therapy #Natural killer cells #Neurodegenerative disorders #NKGen #Phase I trial

Positive early data for Alzheimer’s natural killer cell therapy

NKGen Biotech has announced promising early interim data from the Phase I cohort trial of troculeucel, its cryopreserved autologous enhanced natural killer (NK) cell therapy for moderate Alzheimer’s disease (AD). An early independent review of the Phase I data shows that after three months treatment with… Read More

#Editor's Choice #News

Natural killer cells
#Cell therapy #Imperial College London #Interview #Natural killer cells #NK:IO #Oncology

Natural born killers: University spinout turns NK cell therapy into business

Imperial College spinout NK:IO was awarded a £1.6m ($2m) Innovate UK New Cancer Therapeutics grant in 2023 to develop a pioneering NK cell therapy. Diana Spencer catches up with Co-Founder Mike Romanos to find out more. DS: How can NK cell therapy tackle the limitations of cancer immunotherapy? MR: … Read More

#Cancer Research #Exclusive Content #Opinion #Start-up Zone

#Alzheimer's #Cell therapy #Natural killer cells #Neurodegenerative disorders #NKGen #Phase I trial

The killer instinct: Using natural killer therapy to treat Alzheimer’s

DDW Editor Reece Armstrong speaks to Dr Paul Song, MD, NKGen and Dr Vince DeOrchis, clinician, to find out more about the investigational natural killer therapy SNK01 and the benefit of using a patient’s own cells to treat Alzheimer’s. In October 2023, pharmaceutical company NKGen Biotech… Read More

#Exclusive Content